Lymphomas are a collection of blood cancers stemming from aberrant lymphocytes, which are critical components of the immune system. Lymphomas are classically divided into two categories – Hodgkin lymphoma (HL), and Non-Hodgkin lymphoma (NHL). It is estimated that over 90 percent of lymphomas are NHL, of which there are many distinct subtypes. Recent statistics estimate that nearly 75,000 new cases of NHL will be diagnosed in 2018.Read More
On May 4, the U.S. Food and Drug Administration (FDA) approved a combination of molecularly targeted therapeutics for the treatment of a certain type of thyroid cancer. Specifically, the FDA approved the use of dabrafenib (Tafinlar) in combination with trametinib (Mekinist) for treating patients who have anaplastic thyroid cancer that cannot be removed by surgery or that has metastasized, and that tests positive for a BRAF V600E gene mutation.Read More
While immunotherapy may be the latest tool in the treatment armamentarium for cancer, many ongoing clinical trials are assessing precision medicine approaches that target specific genetic alterations in patient’s tumors.Read More
Norman E. “Ned” Sharpless, MD, who became director of the National Cancer Institute in October 2017, recently unveiled areas of opportunity that he believes are particularly important for accelerating cancer research.Read More
Earlier this week, the U.S. Food and Drug Administration (FDA) approved expanding the use of the immunotherapeutic tisagenlecleucel (Kymriah) to include certain patients with non-Hodgkin lymphoma.
In August 2017, tisagenlecleucel became …
This was another spectacular year for the AACR Annual Meeting with its record-breaking attendance of more than 22,500. From April 14 to April 18, McCormick Place in Chicago was packed …Read More
The AACR Annual Meeting 2018 drew more than 22,600 people to Chicago, providing a front-row seat to some exciting developments in cancer research. Whether it was the practice-changing results of …Read More
A study presented at the AACR Annual Meeting 2018 discussed preliminary data on an off-the-shelf, T-cell receptor (TCR)-less, dual-targeted CD19-CAR T-cell product, FT819. In proof-of-concept preclinical studies, FT819 was found …Read More
Early this week, the U.S. Food and Drug Administration (FDA) approved a combination immunotherapy regimen for treating certain patients newly diagnosed with advanced renal cell carcinoma, the most common form …Read More
This post originally appeared on the Cancer Today website.
Roads and roadblocks, both literal and metaphorical, figured into a panel discussion on the state of cancer research and care in the …
An exciting area in drug development, immunotherapy is being increasingly utilized by patients with different cancer types. These treatments work by stimulating the patient’s immune system to effectively target and …Read More